The global gastroenterology products market is poised for significant growth, with a projected increase from USD 5.15 billion in 2024 to USD 9.66 billion by 2034, reflecting a CAGR of 6.50%. This market encompasses a diverse array of medical devices and pharmaceuticals aimed at diagnosing and treating gastrointestinal (GI) disorders, including endoscopy devices, stents, and biologics. Key drivers of this growth include an aging population and a rising incidence of GI diseases such as gastroesophageal reflux disease (GERD) and colorectal cancer (CRC), alongside advancements in minimally invasive technologies.

The findings indicate that the endoscopy devices segment will dominate the market, supported by innovations in AI-assisted imaging and high-definition visualization that enhance diagnostic accuracy and procedural efficiency. Additionally, the pharmaceuticals and biologics segment is expected to see substantial growth, particularly as personalized medicine approaches gain traction for chronic conditions like inflammatory bowel diseases. The report highlights that hospitals and clinics will remain the primary end-users, driven by their capacity to deliver comprehensive GI care and access to advanced technologies.

The implications of this market trend are significant for ongoing research and development in the field of gastroenterology. The increasing integration of AI technologies and the shift towards non-invasive procedures are likely to reshape the landscape of GI diagnostics and therapeutics, potentially accelerating the timelines for drug development and market entry. This environment presents opportunities for biotech firms to innovate and collaborate on solutions that address the growing demand for effective management of age-related GI health challenges.

Source: globenewswire.com